Showing posts with label Belotecan. Show all posts
Showing posts with label Belotecan. Show all posts
Friday, January 27, 2012
abstract: Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer (total 6 patients/phase 1)
Abstract:
This study was designed to determine the maximum tolerated dose and toxicity profile of belotecan in combination with oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer, fallopian tubal cancer, and primary peritoneal cancer.
"....Thus, the maximum tolerated dose was reached (50 mg of oral etoposide) and the trial was terminated. The response was evaluable in nine patients and an objective response was observed in four patients (44%) including two complete responses."
add your opinions
Belotecan
,
fallopian tube
,
oral etoposide
,
ovarian primary peritoneal cancer
,
platinum resistant
,
toxicities
Subscribe to:
Posts
(
Atom
)